AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20956265 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bundle reconstruction
Number of subjects: 32
Study 20956265 — intervention group
Group type: COMPARATOR
Intervention: Anterior cruciate ligament-deficient knees
Number of subjects: 32
Study 18458586 — intervention group
Group type: EXPERIMENTAL
Intervention: TLIF-A (anterior placement of the semilunar cage)
Number of subjects: 6
Study 18458586 — intervention group
Group type: EXPERIMENTAL
Intervention: TLIF-P (posterior placement of the semilunar cage)
Number of subjects: 6
Study 18458586 — intervention group
Group type: COMPARATOR
Intervention: Comparison between TLIF-A and TLIF-P
Number of subjects: 6
Study 16959668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi program (practiced by 83 subjects)
Number of subjects: 1200
Study 16959668 — intervention group
Group type: COMPARATOR
Intervention: Control group (728 subjects)
Number of subjects: 1200
Study 14501621 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride 60 mg twice daily
Number of subjects: 41
Study 14501621 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride 30 mg three times daily
Number of subjects: 41
Study 14501621 — intervention group
Group type: COMPARATOR
Intervention: Cisapride 20 mg twice daily
Number of subjects: 41
Study 11486420 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with beta-thalassemia major
Number of subjects: 113
Study 11486420 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study 9759061 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexamed 0.1%
Number of subjects: 130
Study 9759061 — intervention group
Group type: COMPARATOR
Intervention: Corsodyl 0.2%
Number of subjects: 130
Study 7917745 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone 2 mg
Number of subjects: 60
Study 7917745 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg
Number of subjects: 60
Study 3421202 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg purified beta‐carotene supplement
Number of subjects: 30
Study 3421202 — intervention group
Group type: COMPARATOR
Intervention: 12 mg beta‐carotene supplement
Number of subjects: 30
Study 3421202 — intervention group
Group type: COMPARATOR
Intervention: 272 g cooked carrots
Number of subjects: 30
Study 3421202 — intervention group
Group type: COMPARATOR
Intervention: 300 g cooked broccoli
Number of subjects: 30
Study 3421202 — intervention group
Group type: COMPARATOR
Intervention: 180 g tomato juice
Number of subjects: 30
Study 3421202 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 31549494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 831
Study 31549494 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 831
Study 28296682 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipated death (withdrawal or withholding of treatment or brain death)
Number of subjects: 698
Study 28296682 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexpected death (despite full-level care or sudden refractory cardiac arrest)
Number of subjects: 698
Study 25539696 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 26
Study 25539696 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 26
Study 25539696 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study 22686292 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg once daily for 6 months
Number of subjects: 173
Study 22686292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 21654733 — intervention group
Group type: EXPERIMENTAL
Intervention: TT genotype of the FKBP5 gene SNP rs1360780
Number of subjects: 2157
Study 21654733 — intervention group
Group type: COMPARATOR
Intervention: CC/CT genotypes of the FKBP5 gene SNP rs1360780
Number of subjects: 2157
Study 21654733 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical abuse with TT genotype of rs1360780
Number of subjects: 2157
Study 18985059 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (3.0 to 20.4 g per day)
Number of subjects: 1717
Study 18985059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1717
Study 17119523 — intervention group
Group type: EXPERIMENTAL
Intervention: Active sports drink (whey and orange juice)
Number of subjects: 18
Study 17119523 — intervention group
Group type: COMPARATOR
Intervention: Placebo (diluted apple juice)
Number of subjects: 18
Study 15152887 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-contact lifestyle interventions
Number of subjects: 50
Study 15152887 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 12761949 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional intra-arterial chemotherapy (IACT)
Number of subjects: 121
Study 12761949 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy (SCT)
Number of subjects: 121
Study 9056054 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide (100 micrograms h-1 after a bolus of 100 micrograms 15 min before the study)
Number of subjects: 8
Study 9056054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9056054 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 8
Study 8346563 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2.5 mg
Number of subjects: 60
Study 8346563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30170329 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (75-600 mg/day)
Number of subjects: 60
Study 30170329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30170329 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 60
Study 26931509 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink (2 mg caffeine per kg body weight; low dose)
Number of subjects: 15
Study 26931509 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink (3 mg caffeine per kg body weight; medium dose)
Number of subjects: 15
Study 26931509 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee (2 mg caffeine per kg body weight)
Number of subjects: 15
Study 26931509 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ml water
Number of subjects: 15
Study 26931509 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 16 oz can of energy drink (16 oz Monster)
Number of subjects: 15
Study 26931509 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 24 oz can of energy drink (24 oz Monster)
Number of subjects: 15
Study 26931509 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 packet of Keurig K-Cup Starbucks coffee
Number of subjects: 15
Study 25203488 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose alcohol
Number of subjects: 145
Study 25203488 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alcohol
Number of subjects: 145
Study 25203488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 22569489 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Exercise (AE)
Number of subjects: 65
Study 22569489 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Aerobic Resistance Exercise (ARE)
Number of subjects: 65
Study 21719808 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair with amalgam (n = 20)
Number of subjects: 50
Study 21719808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing of defective margins (n = 23)
Number of subjects: 50
Study 21719808 — intervention group
Group type: EXPERIMENTAL
Intervention: Refinishing (n = 23)
Number of subjects: 50
Study 21719808 — intervention group
Group type: COMPARATOR
Intervention: Replacement (n = 22)
Number of subjects: 50
Study 21719808 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 25)
Number of subjects: 50
Study 18653326 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (two doses)
Number of subjects: 546
Study 16889588 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicidal ideation in individuals with psychosis
Number of subjects: 290
Study 16889588 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective dysfunction (including distress in response to hallucinations and delusions)
Number of subjects: 290
Study 16889588 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive symptom distress
Number of subjects: 290
Study 16889588 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of auditory hallucinations and preoccupation with delusions
Number of subjects: 290
Study 12924702 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (240 mg/m2 administered intravenously over 20 minutes, followed by infusions of 56 mg/m2/hr)
Number of subjects: 39
Study 12924702 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 39
Study 12924702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 39
Study 12924702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 10808043 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (2 mg)
Number of subjects: 22
Study 10808043 — intervention group
Group type: COMPARATOR
Intervention: Placebo (atmospheric compressed air)
Number of subjects: 22
Study 8858630 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine 0.5%
Number of subjects: 0
Study 8858630 — intervention group
Group type: COMPARATOR
Intervention: Apraclonidine 1%
Number of subjects: 0
Study 1353708 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (500 micrograms.kg‐1 i.v. bolus followed by 150‐300 micrograms.kg‐1.min‐1 maintenance infusion)
Number of subjects: 22
Study 1353708 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (5 mg i.v. bolus followed by 5 mg increments as needed up to a maximum of 1 mg.kg‐1)
Number of subjects: 22
Study 6337524 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural diamorphine 0.1 mg/kg
Number of subjects: 39
Study 6337524 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular diamorphine 0.1 mg/kg
Number of subjects: 39
Study 31485931 — intervention group
Group type: EXPERIMENTAL
Intervention: neoClose® system
Number of subjects: 0
Study 31485931 — intervention group
Group type: COMPARATOR
Intervention: Standard suture closure
Number of subjects: 0
Study 29475804 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (10 mg or 25 mg) plus emtricitabine (200 mg)
Number of subjects: 501
Study 29475804 — intervention group
Group type: COMPARATOR
Intervention: Abacavir (600 mg) plus lamivudine (300 mg)
Number of subjects: 501
Study 29475804 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide plus emtricitabine
Number of subjects: 501
Study 29475804 — intervention group
Group type: COMPARATOR
Intervention: Abacavir plus lamivudine
Number of subjects: 501
Study 26916196 — intervention group
Group type: EXPERIMENTAL
Intervention: Care bundles for patients with COPD
Number of subjects: 0
Study 26916196 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 24564252 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry (IHC) assessment of PTEN loss
Number of subjects: 51
Study 24564252 — intervention group
Group type: EXPERIMENTAL
Intervention: IHC assessment concordance with Taqman® copy number variation (CNV)
Number of subjects: 51
Study 23253713 — intervention group
Group type: EXPERIMENTAL
Intervention: Small laser spot PDT
Number of subjects: 52
Study 20664019 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 5145
Study 20664019 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 5145
Study 17805089 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (1000 mg.d(‐1))
Number of subjects: 40
Study 17805089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14985995 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy subjects (n=10)
Number of subjects: 30
Study 14985995 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic obstructive pulmonary disease (n=10)
Number of subjects: 30
Study 14985995 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure patients (n=10)
Number of subjects: 30
Study 14985995 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy volunteers (n=7) at rest
Number of subjects: 30
Study 14985995 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy volunteers (n=7) during exercise
Number of subjects: 30
Study 14985995 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy volunteers (n=7)
Number of subjects: 30
Study 11133794 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg (500 mg/kg/day for 5 consecutive days, once a month for 3 months)
Number of subjects: 19
Study 11133794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11133794 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of IVIg
Number of subjects: 19
Study 11133794 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-evaluation score
Number of subjects: 19
Study 11133794 — intervention group
Group type: COMPARATOR
Intervention: Electrophysiological studies
Number of subjects: 19
Study 11133794 — intervention group
Group type: COMPARATOR
Intervention: IgM anti-GM1 titres
Number of subjects: 19
Study 11133794 — intervention group
Group type: EXPERIMENTAL
Intervention: High anti-GM1 titres (>3200)
Number of subjects: 19
Study 9700879 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infection patients with CD4+ T-lymphocytes below 200/1
Number of subjects: 0
Study 9700879 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infection patients with non-specific pulmonary diseases
Number of subjects: 0
Study 9700879 — intervention group
Group type: EXPERIMENTAL
Intervention: All stages of HIV infection
Number of subjects: 0
Study 9700879 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stages of HIV infection
Number of subjects: 0
Study 9700879 — intervention group
Group type: EXPERIMENTAL
Intervention: Later stages of HIV infection
Number of subjects: 0
Study 7518629 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0005% iloprost solution
Number of subjects: 148
Study 7518629 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.002% iloprost solution
Number of subjects: 148
Study 7518629 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 148
Study 2594915 — intervention group
Group type: EXPERIMENTAL
Intervention: Received nicotine gum
Number of subjects: 77
Study 2594915 — intervention group
Group type: COMPARATOR
Intervention: Received placebo gum
Number of subjects: 77
Study 2594915 — intervention group
Group type: COMPARATOR
Intervention: Not told which gum received
Number of subjects: 77
Study 2594915 — intervention group
Group type: COMPARATOR
Intervention: Instructions (told received nicotine vs told received placebo)
Number of subjects: 77
Study 2594915 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions and nicotine interaction
Number of subjects: 77
Study 30980539 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin at baseline
Number of subjects: 1731
Study 30980539 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin during concomitant radiochemotherapy (TMZ/RT)
Number of subjects: 1731
Study 30980539 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin monotherapy at baseline
Number of subjects: 1731
Study 30980539 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin monotherapy during TMZ/RT
Number of subjects: 1731
Study 30980539 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus or increased nonfasting glucose levels
Number of subjects: 1731
Study 27727202 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon angioplasty (DCB)
Number of subjects: 106
Study 27727202 — intervention group
Group type: COMPARATOR
Intervention: Plain old balloon angioplasty (POBA)
Number of subjects: 106
Study 25736783 — intervention group
Group type: EXPERIMENTAL
Intervention: EIMD (n = 9)
Number of subjects: 16
Study 25736783 — intervention group
Group type: EXPERIMENTAL
Intervention: EIMD trial 2
Number of subjects: 16
Study 25736783 — intervention group
Group type: EXPERIMENTAL
Intervention: EIMD trial 1
Number of subjects: 16
Study 25736783 — intervention group
Group type: COMPARATOR
Intervention: Control (CON, n = 7)
Number of subjects: 16
Study 23574808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal CO2
Number of subjects: 48
Study 23574808 — intervention group
Group type: COMPARATOR
Intervention: Placebo (air)
Number of subjects: 48
Study 21646929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic steroid injections (ITSIs)
Number of subjects: 60
Study 21646929 — intervention group
Group type: COMPARATOR
Intervention: Intratympanic normal saline injection (ITNI)
Number of subjects: 60
Study 18825421 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg
Number of subjects: 240
Study 18825421 — intervention group
Group type: COMPARATOR
Intervention: Granisetron 3 mg
Number of subjects: 240
Study 17088580 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin
Number of subjects: 4023
Study 17088580 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 4023
Study 14583899 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 9
Study 11199238 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative cancer care workshop
Number of subjects: 68
Study 11199238 — intervention group
Group type: COMPARATOR
Intervention: Control group of non-participants
Number of subjects: 68
Study 9064945 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinaprilat (low dose: 0.5 and 1.0 mg, medium dose: 1.0 and 2.5 mg, high dose: 5.0 and 10.0 mg)
Number of subjects: 50
Study 9064945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1591513 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg i.v. cocaine injections
Number of subjects: 16
Study 1591513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3936095 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (141.7 mg)
Number of subjects: 96
Study 3936095 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthinol nicotinate (500 mg, containing 141.7 mg nicotinic acid)
Number of subjects: 96
Study 3936095 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 96
Study 26699666 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg donepezil
Number of subjects: 30
Study 26699666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30786253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg)
Number of subjects: 1002
Study 30786253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1002
Study 28698321 — intervention group
Group type: EXPERIMENTAL
Intervention: oral oseltamivir plus inhaled zanamivir (arm OZ)
Number of subjects: 541
Study 28698321 — intervention group
Group type: EXPERIMENTAL
Intervention: oseltamivir plus inhaled placebo (arm Opz)
Number of subjects: 541
Study 28698321 — intervention group
Group type: EXPERIMENTAL
Intervention: oral placebo plus inhaled zanamivir (arm poZ)
Number of subjects: 541
Study 28698321 — intervention group
Group type: EXPERIMENTAL
Intervention: inhaled therapy
Number of subjects: 541
Study 28698321 — intervention group
Group type: EXPERIMENTAL
Intervention: oral therapy
Number of subjects: 541
Study 28698321 — intervention group
Group type: EXPERIMENTAL
Intervention: antibiotic coprescriptions
Number of subjects: 541
Study 28698321 — intervention group
Group type: EXPERIMENTAL
Intervention: active combination treatment
Number of subjects: 541
Study 26027851 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 22
Study 26027851 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 22
Study 26027851 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient cohort
Number of subjects: 22
Study 23406672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 40 mg thrice daily
Number of subjects: 70
Study 23406672 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 70
Study 21836046 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg body weight)
Number of subjects: 18
Study 21836046 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 18
Study 21836046 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 18
Study 18394731 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 3605
Study 17309402 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome present at baseline
Number of subjects: 2123
Study 17309402 — intervention group
Group type: COMPARATOR
Intervention: Normal blood glucose levels at baseline
Number of subjects: 2123
Study 17309402 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated fasting glucose level
Number of subjects: 2123
Study 17309402 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 2123
Study 17309402 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes family history
Number of subjects: 2123
Study 17309402 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 2123
Study 17309402 — intervention group
Group type: EXPERIMENTAL
Intervention: High density lipoprotein cholesterol level < 1.0 mmol/L
Number of subjects: 2123
Study 15121405 — intervention group
Group type: EXPERIMENTAL
Intervention: Olpadronate (10 mg/m2 daily)
Number of subjects: 34
Study 15121405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 14644967 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse led smoking cessation intervention
Number of subjects: 240
Study 14644967 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 240
Study 9745100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E2
Number of subjects: 130
Study 9745100 — intervention group
Group type: COMPARATOR
Intervention: Extraamniotic prostaglandin F2alpha
Number of subjects: 130
Study 8017643 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 12
Study 8017643 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 12